All In Biotech

Drug Trial Radar · NCT06379789

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

A Two-Part Open-Label Study of REGV131-LNP1265, A CRISPR/Cas9 Based Coagulation Factor IX Gene Insertion Therapy in Participants With Hemophilia B

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 11, 2024

Primary completion

Aug 14, 2034

Study completion Aug 14, 2047

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
Collaborators
Intellia Therapeutics
First posted
Apr 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. The main aim of this study is to find a safe and well-tolerated dose of the study drug by checking the side effects that may happen from taking it, both in the near term and over time. The study is looking at several other research questions including: * How much study drug is in the blood at different times * Whether the body makes antibodies against parts of the study drug, which could make the drug less effective or could lead to side effects. Antibodies are proteins produced by the body's immune system in response to a foreign substance * Whether the body makes antibodies against the clotting factor replacement therapy * How often factor replacement therapy is needed, both on a regular basis for prevention of bleeding, and as needed to treat bleeding events (and it if changes after taking study drug) * Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood

Conditions

  • Hemophilia B

Interventions

  • REGV131Drug

    Administered per the protocol before LNP1265

  • LNP1265Drug

    Administered per the protocol following REGV131

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 2 Years
  2. Severity of TEAEsTime frame: Up to 2 Years
  3. Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assayTime frame: Up to 2 Years
  4. Change in FIX functional activity in plasma, measured using the chromogenic substrate assayTime frame: Up to 2 Years
  5. Annualized Bleeding Rate (ABR) following sustained FIX functional activity among participants receiving the RDETime frame: Up to 2 Years
  6. Occurrence of Serious Adverse Events (SAEs)Time frame: Through Long Term Follow Up (LTFU), Up to 15 Years
  7. Severity of SAEsTime frame: Through LTFU, Up to 15 Years
  8. Occurrence of Adverse Event of Special Interests (AESIs)Time frame: Through LTFU, Up to 15 Years
  9. Severity of AESIsTime frame: Through LTFU, Up to 15 Years
  10. Occurrence of clinically meaningful Adverse Events (AEs)Time frame: Through LTFU, Up to 15 Years
  11. Severity of clinically meaningful AEsTime frame: Through LTFU, Up to 15 Years

Locations

54 sites in 9 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Orthopaedic Hemophilia Treatment Center

    Los Angeles, California · Recruiting

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California · Recruiting

  • University of California Davis

    Sacramento, California · Recruiting

  • University California San Francisco

    San Francisco, California · Recruiting

  • University of Colorado Hemophilia and Thrombosis Center

    Aurora, Colorado · Recruiting

  • Yale HTC

    New Haven, Connecticut · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Indiana Hemophilia and Thrombosis Center

    Indianapolis, Indiana · Recruiting

  • Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders

    New Orleans, Louisiana · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Nationwide Children's Hospital

    Columbus, Ohio · Recruiting

  • Children's Hospital of Philadelphia (CHOP)

    Philadelphia, Pennsylvania · Recruiting

  • Hemophilia Center of Western Pennsylvania

    Pittsburgh, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Children's Medical Center Dallas

    Dallas, Texas · Recruiting

  • University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

  • Royal Prince Alfred Hospital, Haemophilia Treatment Centre

    Camperdown, New South Wales, Australia · Recruiting

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Hemorio

    Rio de Janeiro, Brazil · Recruiting

  • Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos

    Vitória, Espírito Santo, Brazil · Recruiting

  • Hemocentro Unicamp

    Campinas, São Paulo, Brazil · Recruiting

  • University of Alberta Hospital

    Edmonton, Alberta, Canada · Recruiting

  • McMaster University Medical Centre - Hamilton Health Sciences

    Hamilton, Ontario, Canada · Recruiting

  • McGill University Health Center (MUHC)

    Montreal, Quebec, Canada · Recruiting

  • Hopital Necker

    Paris, Île-de-France Region, France · Recruiting

  • Hospices Civils de Lyon

    Bron, Lyon, France · Recruiting

  • Hemostase Clinique, Institut Coeur Poumon

    Lille, Nord, France · Recruiting

  • University Hospital Hamburg Eppendorf

    Hamburg, Germany · Recruiting

  • University Hospital Frankfurt

    Frankfurt am Main, Hesse, Germany · Recruiting

  • University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine

    Bonn, North Rhine-Westphalia, Germany · Recruiting

  • Ospedale san Bortolo

    Vicenza, Italy · Recruiting

  • Careggi University Hospital

    Florence, Firenze, Italy · Recruiting

  • Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy · Recruiting

  • Irccs Humanitas Research Hospital

    Rozzano, Lombardy, Italy · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.